Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosedhigh-grade glioma
Autore:
Buckner, JC; Schomberg, PJ; McGinnis, WL; Cascino, TL; Scheithauer, BW; OFallon, JR; Morton, RF; Kuross, SA; Mailliard, JA; Hatfield, AK; Cole, JT; Steen, PD; Bernath, AM;
Indirizzi:
Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Fdn, Rochester, MN 55905 USA Iowa Oncol Res Assoc CCOP, Des Moines, IA USA Iowa Oncol Res Assoc CCOP Des Moines IA USA soc CCOP, Des Moines, IA USA Duluth CCOP, Duluth, MN USA Duluth CCOP Duluth MN USADuluth CCOP, Duluth, MN USA Carle Canc Ctr CCOP, Urbana, IL USA Carle Canc Ctr CCOP Urbana IL USACarle Canc Ctr CCOP, Urbana, IL USA Ochsner CCOP, New Orleans, LA USA Ochsner CCOP New Orleans LA USAOchsner CCOP, New Orleans, LA USA Meritcare Hosp CCOP, Fargo, ND USA Meritcare Hosp CCOP Fargo ND USAMeritcare Hosp CCOP, Fargo, ND USA Geisinger Clin, Danville, PA USA Geisinger Clin Danville PA USAGeisinger Clin, Danville, PA USA Med Ctr CCOP, Danville, PA USA Med Ctr CCOP Danville PA USAMed Ctr CCOP, Danville, PA USA Creighton Univ, Nebraska Oncol Grp, Univ Nebraska Med Ctr & Associates, Omaha, NE 68178 USA Creighton Univ Omaha NE USA 68178 d Ctr & Associates, Omaha, NE 68178 USA
Titolo Testata:
CANCER
fascicolo: 2, volume: 92, anno: 2001,
pagine: 420 - 433
SICI:
0008-543X(20010715)92:2<420:APISOR>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT GLIOMAS; BCNU; RADIOTHERAPY; CHEMOTHERAPY; SURGERY; TRIAL;
Keywords:
glioma; carmustine (BCNU); interferon-alpha (IFN-alpha); radiation; time to disease progression; overall survival;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Buckner, JC Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin 200 1st St SW Rochester MN USA 55905 r, MN 55905 USA
Citazione:
J.C. Buckner et al., "A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosedhigh-grade glioma", CANCER, 92(2), 2001, pp. 420-433

Abstract

BACKGROUND, The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy andcarmustine (BCNU) improves time to disease progression or overall survivalin patients with high-grade glioma. METHODS. Patients with anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma multiforme, or gliosarcoma received radiation therapy plus BCNU as initial therapy. Subsequently, patients without tumor progression atthe completion of radiation therapy were stratified by age, extent of surgery, tumor grade and histology, Eastern Cooperative Oncology Group performance status, and treating institution, and then were randomly assigned to receive either BCNU alone (200 mg/m(2) on Day 1) or BCNU (150 mg/m(2) on Day 3) plus IFN-alpha (12 million U/m(2) on Days 1-3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles. RESULTS. Of the 383 patients enrolled in the study, 275 eligible patients were randomized. There was no significant difference with regard to time todisease progression or overall survival between the two groups. Patients receiving IFN-a! experienced more fever, chills, myalgias, and neurocorticalsymptoms including somnolence, confusion, and exacerbation of neurologic deficits. Cox multivariate regression models confirmed known favorable prognostic variables including younger age, Grade 3 tumor [according to World Health Organization criteria), and greater extent of surgery. Cox and classification and regression tree analysis models also demonstrated that a normalbaseline Folstein mini-mental status examination (MMSE) score was associated with better prognosis. CONCLUSIONS. IFN-alpha does not appear to improve time to disease progression or overall survival in patients with high-grade glioma and appears to add significantly to toxicity. The baseline MMSE score may serve as an independent prognostic factor and warrants further investigation. (C) 2001 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:33:00